See Playground which can speak better than any words. See Performance page which demonstrate the library performance.
C4 Therapeutics (CCCC) on Thursday announced a new collaboration with its long-standing partner Roche (RHHBY) (RHHBF) to develop a new class of cancer drugs called degrader-antibody conjugates (DACs).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results